Palantir’s Two-Sided Coin: Record Operations vs. a European Revolt
Published on 07/30/2026 at 21:10 | Redaktion boerse-global.de
The gap between Palantir’s operational performance and its stock price has rarely been wider. The company is delivering double-digit revenue growth and raising its full-year guidance, yet the shares have shed nearly a third of their value since January. At €105.92, the stock sits more than 40% below its 52-week high of €179.98 — a chasm that has little to do with the US commercial engine and everything to do with a coordinated European backlash.
That disconnect will be put to the test when Palantir reports second-quarter results in early August. Analysts are looking for revenue of roughly $1.8 billion, a sharp year-over-year increase, with earnings per share near $0.35. Those figures align with management’s existing forecast, and the market will be watching closely whether the company can maintain its “Rule of 40” metric — a blend of revenue growth and profit margin that hit 145% last quarter. If that number holds, the bull case gets a powerful tailwind.
Europe’s Digital Sovereignty Push
The most significant headwind isn’t coming from Silicon Valley or Wall Street — it’s coming from Paris and Berlin. France’s domestic intelligence agency, DGSI, is replacing Palantir’s analytics software with a solution from the French provider ChapsVision. Prime Minister Sébastien Lecornu justified the move in stark terms, arguing that France cannot tolerate “strategic dependencies” in the digital sphere. Germany’s intelligence service has followed suit, also opting for ChapsVision. This is not a series of isolated defections but a coordinated European push for digital sovereignty.
The loss of two of the continent’s largest economies as government clients strikes at the heart of Palantir’s growth narrative, which has long been built on the idea of global indispensability in the public sector. For a stock that still trades at a lofty valuation, these exits introduce a political risk premium that no amount of US commercial success can fully erase.
Should investors sell immediately? Or is it worth buying Palantir?
A Second Blow in the UK
Across the English Channel, the picture is no brighter. Palantir and the UK’s National Health Service had touted their “Optica” discharge-planning tool as a success story, claiming it reduced delays for long-stay patients. But an independent analysis by the Health Foundation found “no noticeable improvement” and “no meaningful difference” in the hospitals using the tool. NHS England has now commissioned Imperial College to conduct its own independent evaluation, while the UK statistics authority has demanded tighter restrictions on any claimed causal link between the tool and purported improvements.
For a company whose valuation rests heavily on the narrative of being irreplaceable in government operations, this contradiction carries weight. The UK setback compounds the European trust crisis and raises questions about whether Palantir’s public-sector expansion can continue at the pace investors have priced in.
Analyst Optimism vs. Market Reality
Despite the mounting headwinds, Rosenblatt Securities remains firmly in the bull camp. In a note dated July 30, the bank reiterated its “Buy” rating and a price target of $225 — implying more than a doubling from current levels. The firm is betting that Palantir’s US commercial business, particularly its AI-driven platform, can more than offset the European losses.
That view is not universally shared. Hedge fund positioning tells a story of deep division: while the number of funds holding Palantir shares rose in the first quarter, prominent short sellers like Michael Burry have maintained their bearish bets. Burry’s argument is unchanged — the valuation, even after the recent slide, remains too aggressive for a company with such concentrated political risks. The market capitalization stands at €276.89 billion, and the consensus analyst price target of €159.99 implies upside of roughly 49% — a spread that underscores just how wide the gulf between optimism and reality has become.
New Partnerships and Technical Signals
While the stock consolidates, Palantir continues to expand its commercial footprint. The company announced a partnership with Zeta Global to integrate AI infrastructure into marketing, and it has deepened its presence in Mexico through a deal with insurer GNP Seguros. Institutional interest is also evident: IFS Group LLC built a new position in the first half of the year.
Palantir at a turning point? This analysis reveals what investors need to know now.
Technically, the stock is trading nearly 19% below its 200-day moving average of €130.64 — a level that often signals a market in distress. The combination of a stretched valuation, European political defections, and a UK credibility problem creates a precarious setup heading into earnings.
The August report will be a defining moment. If Palantir delivers on the $1.8 billion revenue line and keeps the Rule of 40 near 145%, Rosenblatt’s bullish thesis gains tangible support. But if those numbers fall short, the year-to-date downtrend is unlikely to reverse. For now, the stock remains caught between stellar operations and punishing expectations — a tension that only the next quarterly print can resolve.
Ad
Palantir Stock: New Analysis - 30 July
Fresh Palantir information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
